Leishmaniasis is one of the oldest zoonotic diseases faced by humans since 650 before Christ (BC). This commonplace infection is caused by a kinetoplastid parasite, “
Leishmania” (family
Trypanosomatidae), with a wide range of manifestations, from painless lesions or severe cutaneous wounds (due to
Leishmania major) to visceral form (owing to
Leishmania donovani) (
1). The female sand flies of the genera Lutzomyia (in the new world) and Phlebotomus (in the old world) are the main vectors of Leishmaniasis, which transfer the promastigote form to the susceptible host. Nonetheless, this infection remains to be an important public health issue and has remarkably drawn attention of hygiene surveillance systems to take necessary measures. Two genera of Leishmania render the cutaneous form in Iran, namely
Leishmania tropica and
L. major. The annual morbidity and mortality rate of cutaneous leishmaniasis (CL) are 1.5 million cases and 7000 deaths, respectively. The incidence rate of CL is increasing annually, because of co-incidence with immune deficiency diseases such as human immunodeficiency virus (HIV), international travel as well as refugees coming from endemic regions (
2,
3).
Chemotherapy and immunoprophylaxis of Leishmaniasis are of utmost importance (
4). Due to its long-term therapy, treatment of Leishmaniasis has become a great challenge. The principal first-line therapies to treat CL are pentavalent antimonial compounds such as sodium stibogluconate or Pentostam and meglumine antimoniate, whereas the second-line therapies are Pentamidine and Amphotericin B. However, these medications are expensive with low availability, undesired side effects (nausea, vomiting) and relapse while drug resistance has been reported after their use (
5). Hence, there is an urgent need to find novel drugs and compounds, which possess minimum complications, and are available and economical. However, many researches have been performed assessing the effect of synthetic and/or natural products on these parasites to discriminate their leishmanicidal activity, but they have had different efficacies and, so far, there isn’t any novel therapy available. According to the World health organization (WHO) publications, plants are among the best and the largest repositories of biomedical compounds for humans; therefore, evaluation of herbal extracts could lead us to cutting-edge treatment of cutaneous leishmaniasis (
6). Chaerophyllum (family
Apiaceae) consists of 110 species of fragrant shrubs, of which eight species exist in Iran and grow predominantly in North temperate areas.
Chaerophyllum macropodum Boiss is a known and characterized species, growing in many geographical territories, with its aerial parts being used occasionally as edible vegetable and in preparation of foods and cheese in Iran and Turkey (
7-
10).